Compare EVO & TLRY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVO | TLRY |
|---|---|---|
| Founded | 1993 | N/A |
| Country | Germany | Canada |
| Employees | 4766 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 895.8M | 919.2M |
| IPO Year | N/A | 2018 |
| Metric | EVO | TLRY |
|---|---|---|
| Price | $2.76 | $6.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $7.00 | ★ $79.25 |
| AVG Volume (30 Days) | 106.1K | ★ 2.5M |
| Earning Date | 04-08-2026 | 04-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.25 |
| Revenue Next Year | $0.21 | $16.97 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $0.36 |
| 52 Week High | $4.80 | $15.70 |
| Indicator | EVO | TLRY |
|---|---|---|
| Relative Strength Index (RSI) | 52.81 | 50.57 |
| Support Level | $2.32 | $1.12 |
| Resistance Level | $3.75 | $7.08 |
| Average True Range (ATR) | 0.08 | 0.42 |
| MACD | 0.07 | 0.07 |
| Stochastic Oscillator | 85.57 | 81.52 |
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.
Tilray is a Canadian producer that cultivates and sells medical and recreational cannabis. In 2021, legacy Aphria acquired legacy Tilray in a reverse merger and renamed itself Tilray. The bulk of its sales are in Canada and in the international medical cannabis export market. US exposure comes mainly from alcohol.